The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix
Open accessAbstract
We studied the interactions of phosphorothioate oligodeoxynucleotides and heparin-binding growth factors. By means of a gel mobility shift assay, we demonstrated that phosphodiester and phosphorothioate homopolymers bound to basic fibroblast growth factor (bFGF). Binding of a probe phosphodiester oligodeoxynucleotide could also be shown for other proteins of the FGF family, including acidic fibroblast growth factor (aFGF), Kaposi's growth factor (FGF-4) as well as for the bFGF-related vascular endothelial growth factor, VEGF. No binding to epidermal growth factor (EGF) was observed. In addition, using a radioreceptor assay, we have shown that phosphorothioate homopolymers of cytidine and thymidine blocked binding of not only 125I-bFGF, but also of 125I-PDGF to NIH 3T3 cells, whereas phosphodiester oligodeoxynucleotides were ineffective. The extent of blockade of binding was dependent on the chain length of the phosphorothioate oligodeoxynucleotide. Furthermore, we have examined the effects of 18-mer phosphorothioate oligodeoxynucleotides of different sequences on 125I-bFGF binding to low and high affinity sites on both NIH 3T3 fibroblasts and DU-145 prostate cancer cells. Despite the fact that we have observed inhibition of bFGF binding by the 18-mer phosphorothioate oligodeoxynucleotides for both the high and low affinity classes of bFGF receptor, the inhibition was sequence-selective only for the high affinity receptors. We have also demonstrated that phosphorothioate homopolymers of cytidine and thymidine release bFGF bound to low affinity receptors in extracellular matrix (ECM). Finally, the most potent phosphorothioate oligodeoxynucleotides used in these experiments (e.g. SdC28) were inhibitors of bFGF-induced DNA synthesis in NIH 3T3 cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C. A., & Cheng, Y.-C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,303
Self-citationVlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai-Michaeli, R., Sasse, J., & Klagsbrun, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.8.2292 · Cited by 1,032
Self-citationFolkman, J., Klagsbrun, M., Sasse, J., Wadzinski, M., Ingber, D. E., & Vlodavsky, I. (1988) · PubMed Central · Cited by 875
Self-citationAntisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
Simons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R., & Rosenberg, R. D. (1992) · Nature · doi:10.1038/359067a0 · Cited by 731
Moscatelli, D. (1987) · Journal of Cellular Physiology · doi:10.1002/jcp.1041310118 · Cited by 646
Physicochemical properties of phospborothioate oligodeoxynucleotides
Stein, C. A., Subasinghe, C., Shinozuka, K., & Cohen, J. S. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.8.3209 · Cited by 591
Self-citationBashkin, P., Doctrow, S., Klagsbrun, M., Svahn, C. M., Folkman, J., & Vlodavsky, I. (1989) · Biochemistry · doi:10.1021/bi00430a047 · Cited by 590
Self-citationGonzalez, A. M., Buscaglia, M., Ong, M., & Baird, A. (1990) · The Journal of cell biology · doi:10.1083/jcb.110.3.753 · Cited by 527
Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells
Coffey, R. J., Leof, E. B., Shipley, G. D., & Moses, H. L. (1987) · Journal of Cellular Physiology · doi:10.1002/jcp.1041320120 · Cited by 379
Suramin: an anticancer drug with a unique mechanism of action.
Stein, C. A., LaRocca, R. V., Thomas, R., McAtee, N., & Myers, C. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.499 · Cited by 375
Self-citationGospodarowicz, D., Mescher, A. L., & Birdwell, C. R. (1977) · Experimental Eye Research · doi:10.1016/0014-4835(77)90248-2 · Cited by 337
Three-dimensional structure of human basic fibroblast growth factor.
Eriksson, A. E., Cousens, L. S., Weaver, L. H., & Matthews, B. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3441 · Cited by 284
Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?
Vlodavsky, I., Bar-Shavit, R., Ishar-Michael, R., Bashkin, P., & Fuks, Z. (1991) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(91)90102-2 · Cited by 283
Self-citationRoghani, M., Mansukhani, A., Dell'Era, P., Bellosta, P., Basilico, C., Rifkin, D. B., & Moscatelli, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41730-3 · Cited by 261
Expression of basic fibroblast growth factor in normal human tissues.
Cordon‐Cardo, C., Vlodavsky, I., Haimovitz‐Friedman, A., Hicklin, D. J., & FUKS, Z. Y. (1990) · PubMed · Cited by 258
Self-citationZhang, J. D., Cousens, L. S., Barr, P. J., & Sprang, S. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3446 · Cited by 250
Stein, C. A., & Krieg, A. M. (1994) · Antisense Research and Development · doi:10.1089/ard.1994.4.67 · Cited by 228
Self-citationSuramin: a novel antineoplastic agent with multiple potential mechanisms of action.
Stein, C. (1993) · PubMed · Cited by 227
Self-citationWilliams, L. T., Tremble, P. M., Lavin, M. F., & Sunday, M. E. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42987-5 · Cited by 202
High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding.
Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11227 · Cited by 149
Moscatelli, D., & Quarto, N. (1989) · The Journal of Cell Biology · doi:10.1083/jcb.109.5.2519 · Cited by 141
Weiner, H. L., & Swain, J. L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2683 · Cited by 137
Zugmaier, G., Lippman, M. E., & Wellstein, A. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.22.1716 · Cited by 133
Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial
Eisenberger, M. A., Reyno, L. M., Jodrell, D. I., Sinibaldi, V. J., Tkaczuk, K. H. R., Sridhara, R. N., Zuhowski, E. G., Lowitt, M. H., Jacobs, S. C., & Egorin, M. J. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.611 · Cited by 129
Bikfalvi, A., Sauzeau, C., Moukadiri, H., Maclouf, J., Busso, N., Bryckaert, M., Plouët, J., & Tobelem, G. (1991) · Journal of Cellular Physiology · doi:10.1002/jcp.1041490108 · Cited by 123
Yayon, A., & Klagsbrun, M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5346 · Cited by 118
Wellstein, A., Zugmaier, G., Califano, J. A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.10.716 · Cited by 105
Binding of heparin to basic fibroblast growth factor induces a conformational change
Prestrelski, S. J., Fox, G. M., & Arakawa, T. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90401-h · Cited by 103
Fibroblast growth factor-2 (FGF-2) in the nucleus: Translocation process and targets
Amalric, F., Bouche, G., Bonnet, H., Brethenou, P., Roman, A. M., Truchet, I., & Quarto, N. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90443-x · Cited by 96
Ishai-Michaeli, R., Svahn, C. M., Weber, M., Chajek-Shaul, T., Korner, G., Ekre, H. P., & Vlodavsky, I. (1992) · Biochemistry · doi:10.1021/bi00122a027 · Cited by 87
Self-citationNovel Mechanisms of Fibroblast Growth Factor 1 Function
Maciag, T., Zhan, X., Garfinkel, S., Friedman, S. A., Prudovsky, I. A., JACKSON, A., Wessendorf, J., HU, X., Gamble, S., SHI, J., et al. (1994) · Elsevier eBooks · doi:10.1016/b978-0-12-571149-4.50009-x · Cited by 16
Cited by
CpG Motifs in Bacterial DNA and Their Immune Effects
Krieg, A. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,573
Antisense technologies: Improvement through novel chemical modifications
Kurreck, J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03555.x · Cited by 1,006
Design of antisense oligonucleotides stabilized by locked nucleic acids
Kurreck, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.1911 · Cited by 577
CNS Drug Design Based on Principles of Blood‐Brain Barrier Transport
Pardridge, W. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70051781.x · Cited by 460
The Medicinal Chemistry of Therapeutic Oligonucleotides
Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 429
Metadata
- Authors
- Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L., & Stein, C. A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1995-02
- Volume
- 270
- Issue
- 6
- Pages
- 2620-2627
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2016696388
- Cited by
- 326
- References
- 34
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.